HealthInvest Partners AB
Latest statistics and disclosures from Atle Fund Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, MRK, JNJ, ABBV, CVS, and represent 30.43% of Atle Fund Management AB's stock portfolio.
- Added to shares of these 10 stocks: MRK (+$20M), BIIB (+$14M), CVS (+$13M), IONS (+$8.7M), TNGX (+$5.3M), ORKA (+$5.2M), NAMS (+$5.2M), BSX, IRTC, ABVX.
- Started 3 new stock positions in ORKA, JBIO, BIIB.
- Reduced shares in these 10 stocks: RVMD (-$102M), DXCM (-$35M), BCAX (-$30M), CAH (-$20M), ISRG (-$18M), LLY (-$12M), CELC (-$11M), MIRM (-$11M), ABBV (-$11M), AMGN (-$8.7M).
- Sold out of its positions in AMGN, Soleno Therapeutics, UNH.
- Atle Fund Management AB was a net seller of stock by $-191M.
- Atle Fund Management AB has $372M in assets under management (AUM), dropping by 20.03%.
- Central Index Key (CIK): 0001381843
Tip: Access up to 7 years of quarterly data
Positions held by HealthInvest Partners AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Atle Fund Management AB
Atle Fund Management AB holds 39 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 9.6 | $36M | -24% | 30k | 1199.43 |
|
| Merck & Co (MRK) | 6.5 | $24M | +459% | 189k | 128.50 |
|
| Johnson & Johnson (JNJ) | 5.8 | $22M | -7% | 85k | 253.97 |
|
| Abbvie (ABBV) | 4.4 | $16M | -40% | 64k | 251.64 |
|
| CVS Caremark Corporation (CVS) | 4.1 | $15M | +514% | 146k | 103.45 |
|
| Thermo Fisher Scientific (TMO) | 3.8 | $14M | +21% | 28k | 501.36 |
|
| Revolution Medicines (RVMD) | 3.7 | $14M | -88% | 73k | 187.28 |
|
| Biogen Idec (BIIB) | 3.6 | $14M | NEW | 63k | 216.06 |
|
| Neurocrine Biosciences (NBIX) | 3.3 | $12M | -18% | 73k | 168.53 |
|
| Mirum Pharmaceuticals (MIRM) | 3.2 | $12M | -48% | 101k | 117.07 |
|
| Alkermes SHS (ALKS) | 3.0 | $11M | -12% | 213k | 52.40 |
|
| Ionis Pharmaceuticals (IONS) | 2.9 | $11M | +391% | 137k | 79.29 |
|
| Beone Medicines Ltd- Sponsored Ads (ONC) | 2.7 | $10M | -15% | 35k | 284.97 |
|
| Intuitive Surgical Com New (ISRG) | 2.6 | $9.8M | -65% | 25k | 397.68 |
|
| Stryker Corporation (SYK) | 2.6 | $9.5M | +12% | 30k | 314.84 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.6 | $9.5M | -16% | 19k | 496.73 |
|
| Edwards Lifesciences (EW) | 2.5 | $9.3M | -3% | 103k | 90.46 |
|
| Bridgebio Pharma (BBIO) | 2.5 | $9.3M | +11% | 125k | 74.48 |
|
| Krystal Biotech (KRYS) | 2.4 | $8.9M | -36% | 24k | 371.67 |
|
| AmerisourceBergen (COR) | 2.4 | $8.8M | +32% | 31k | 282.98 |
|
| Newamsterdam Pharma Co Nv Ordinary Shares (NAMS) | 2.3 | $8.4M | +162% | 249k | 33.89 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.1 | $7.8M | +84% | 58k | 133.26 |
|
| Incyte Corporation (INCY) | 1.7 | $6.5M | +12% | 57k | 113.36 |
|
| Irhythm Technologies (IRTC) | 1.7 | $6.4M | +142% | 54k | 118.95 |
|
| Boston Scientific Corporation (BSX) | 1.7 | $6.2M | +262% | 146k | 42.68 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $6.2M | -40% | 58k | 106.62 |
|
| Tango Therapeutics (TNGX) | 1.7 | $6.2M | +563% | 199k | 31.26 |
|
| Gilead Sciences (GILD) | 1.6 | $5.8M | -3% | 46k | 126.34 |
|
| Cardinal Health (CAH) | 1.5 | $5.6M | -78% | 24k | 237.56 |
|
| Oruka Therapeutics (ORKA) | 1.4 | $5.2M | NEW | 55k | 95.17 |
|
| Spyre Therapeutics Com New (SYRE) | 1.4 | $5.1M | -9% | 57k | 88.78 |
|
| Dexcom Com New (DXCM) | 1.3 | $4.8M | -87% | 72k | 67.35 |
|
| Bicara Therapeutics (BCAX) | 1.2 | $4.3M | -87% | 146k | 29.69 |
|
| Ideaya Biosciences (IDYA) | 0.9 | $3.5M | +203% | 95k | 37.27 |
|
| Celcuity (CELC) | 0.9 | $3.5M | -76% | 33k | 104.62 |
|
| Disc Medicine (IRON) | 0.9 | $3.2M | -59% | 44k | 73.14 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.8 | $2.9M | +390% | 967k | 3.01 |
|
| Compass Therapeutics (CMPX) | 0.6 | $2.3M | +2406% | 1.0M | 2.19 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $2.0M | NEW | 89k | 22.22 |
|
Past Filings by Atle Fund Management AB
SEC 13F filings are viewable for Atle Fund Management AB going back to 2013
- Atle Fund Management AB 2026 Q2 filed July 24, 2026
- Atle Fund Management AB 2026 Q1 filed May 11, 2026
- Atle Fund Management AB 2025 Q4 filed Feb. 6, 2026
- Atle Fund Management AB 2025 Q3 filed Nov. 4, 2025
- Atle Fund Management AB 2025 Q2 filed July 14, 2025
- Atle Fund Management AB 2025 Q1 filed May 5, 2025
- HealthInvest Partners AB 2024 Q4 filed Feb. 4, 2025
- HealthInvest Partners AB 2024 Q3 filed Nov. 12, 2024
- HealthInvest Partners AB 2024 Q1 filed April 25, 2024
- HealthInvest Partners AB 2023 Q4 filed Jan. 30, 2024
- HealthInvest Partners AB 2022 Q4 filed Feb. 14, 2023
- HealthInvest Partners AB 2022 Q3 filed Oct. 21, 2022
- HealthInvest Partners AB 2022 Q2 filed July 8, 2022
- HealthInvest Partners AB 2022 Q1 filed May 5, 2022
- HealthInvest Partners AB 2021 Q4 filed Jan. 18, 2022
- HealthInvest Partners AB 2021 Q3 filed Nov. 8, 2021